Protein clue to tailor-made antibioticsAugust 23, 2006Scientists at the University of York have made a huge leap forward in the search for 'smarter' antibiotics. A research group in the Department of Biology has made a significant advance in understanding how bacteria use proteins to conduct a type of biological warfare. Bacteria like E. coli frequently try to kill each other when resources are scarce using protein antibiotics called colicins, which are potent toxins. The research led by Professor Colin Kleanthous has discovered a critical element in the mode of action of a class of colicins (so-called DNases) that kill cells by destroying their DNA. Though most proteins have a folded structure, DNase colicins are only partially so. The scientists have found that the unfolded part of DNase colicin structure makes its way into an unsuspecting bacterium and blocks a key process that lowers the cell's defences and allows the toxin to enter. The research, which was supported by the Wellcome Trust and the Biotechnology and Biological Sciences Research Council, is published in the latest edition of the Proceedings of the National Academy of Sciences (PNAS). Professor Kleanthous said: "Antibiotic resistance is on the increase throughout the world. Understanding how bacteria have evolved to kill each other with protein toxins might offer ways of constructing new, tailor-made antibiotics that target particular microorganisms." Researchers are now trying to establish what it is about this blocking mechanism (which they've christened 'competitive recruitment') that lowers the cells' defences toward the colicin. University of York |
|||||||||||||||||||||
| Related Antibiotics Current Events and Antibiotics News Articles New study finds MRSA on the rise in hospital outpatients The community-associated strain of the deadly superbug MRSA-an infection-causing bacteria resistant to most common antibiotics-poses a far greater health threat than previously known and is making its way into hospitals, according to a study in the December issue of Emerging Infectious Diseases. A Second Skin Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. New imagining technique could lead to better antibiotics and cancer drugs A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist. UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. Progress made on group B streptococcus vaccine Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. Henry Ford Hospital study: A MRSA strain linked to high death rates A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Pumpkin skin may scare away germs The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year. Deadly stomach infection rising in community settings, Mayo Clinic study finds Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings. More Antibiotics Current Events and Antibiotics News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||